

Hosted By
50 Went
Drug Development Inside Big Pharma with GSK
Hosted by Oxford Biotech Society
Registration
Sold Out
This event is sold out and no longer taking registrations.
About Event
Next generation biologics discovery in oncology
Dr Johannes Breuning obtained his PhD in 2016 from the University of Oxford in molecular immunology focusing on T cell receptor signalling. After a Postdoc in the same lab, he started a position as investigator at GSK in the Oncology Cell Therapy group in 2018, developing novel cell therapies for solid cancer. Johannes transitioned to working on biologics in in the oncology space in 2022, focusing on T cell engager and antibody drug conjugates. His work spans from early discovery of novel drug targets and drugs to supporting clinical trials with experimental biology. Johannes also leads multiple academic collaborations examining mechanistic details of T cell engager biology.
Location
Roy Griffiths Lecture Room - Keble College
Hosted By
50 Went